Evidence map›Paper›PMID 27730396›Full record

ArticleHandbook of experimental pharmacology

Principles of Ocular Pharmacology.

Yong Park, Dorette Ellis, Brett Mueller, Dorota Stankowska, Thomas Yorio

Open access · bronzeAbstract read
In one paragraph

Article in Handbook of experimental pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Yong ParkNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA.
Dorette EllisNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA.
Brett MuellerDepartment of Ophthalmology, University of Louisville, Louisville, KY, USA.
Dorota StankowskaNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA.
Thomas YorioNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA. Thomas.Yorio@unthsc.edu.
University of North Texas Health Science Center · USSmith-Kettlewell Eye Research Institute · USUniversity of Louisville · USUniversity of North Texas · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, in a poll by Research America, a significant number of individuals placed losing their eyesight as having the greatest impact on their lives more so than other conditions, such as limb loss or memory loss. When they were also asked to rank which is the worst disease that could happen to them, blindness was ranked first by African-Americans and second by Caucasians, Hispanics, and Asians. Therefore, understanding the mechanisms of disease progression in the eye is extremely important if we want to make a difference in people's lives. In addition, developing treatment programs for these various diseases that could affect our eyesight is also critical. One of the most effective treatments we have is in the development of specific drugs that can be used to target various components of the mechanisms that lead to ocular disease. Understanding basic principles of the pharmacology of the eye is important if one seeks to develop effective treatments. As our population ages, the incidence of devastating eye diseases increases. It has been estimated that more than 65 million people suffer from glaucoma worldwide (Quigley and Broman. Br J Ophthalmol 90:262-267, 2006). Add to this the debilitating eye diseases of age-related macular degeneration, diabetic retinopathy, and cataract, the number of people effected exceeds 100 million. This chapter focuses on ocular pharmacology with specific emphasis on basic principles and outlining where in the various ocular sites are drug targets currently in use with effective drugs but also on future drug targets.

Indexed as

Disease ProgressionEye DiseasesHumansOcular drugsOcular PharmacologyPharmacodynamics

Identifiers

PMID27730396
PMCPMC7122473
OpenAlexW2531378471

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.